Skip to main content
Premium Trial:

Request an Annual Quote

More from the Hardware Front: Sun Launches Sun Fire 15K Server

Premium

As competition heats up on the hardware side of the life sciences computing market, Sun Microsystems added to the fray last week with the launch of its new flagship high-end system: the Sun Fire 15K server.

The system is the next generation of the company’s Star Fire server, according to Sia Zadeh, group marketing manager at Sun. He said that the new server’s scalability should make it especially promising for the life sciences market.

Users can start with a very small configuration and scale “from the same simple system that they use on the desktop to a very large configuration in terms of both the number of processors, the memory configuration, and the volume of data it can handle,” Zadeh said.

Zadeh added that the Sun Fire 15K was developed with input from Sun’s partners and end-users in the life science community, such as Oxford GlycoSciences and Caprion Pharmaceuticals “to make sure we’re developing platforms and technologies to meet their needs and challenges.”

In contrast to its competitors, who are “cutting back on their life sciences investments,” Sun’s commitment to the sector remains strong, Zadeh said. “Our partners and end-users have been burned by companies who had good technology at one time but who were not able to sustain their business model.”

Despite a warning by Sun CFO Mike Lehman during the company’s mid-quarter conference call on August 29 that, “due to performance management, attrition, and reduction of a few programs, we expect to exit the quarter with around 500 people less than the end of Q4,” Zadeh said Sun’s life sciences operation should remain intact.

“Life science is definitely viewed by Sun Microsystems as a growth market,” Zadeh said. “If anything we are actually increasing our investment and commitment to this space.”

— BT

 

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.